Moreover, our data demonstrated that re-expression of a functional FAM46C in MM cells synergized with administration of SphK1/SphK2 inhibitor SKI-I [6], suggesting that targeting the SphK pathway in FAM46C-expressing cells might be a promising therapeutic strategy for MM treatment. This evidence concerns the gene SPHK1 and Miyoshi myopathy.